Symptomtext
Patient is almost 2 months old, and was inadvertently administered a 0.5 mL dose of Fluzone Quadrivalent from the 5mL multi-dose vial today (14 Jan 2022).; Initial information received on 14-Jan-2022 regarding an unsolicited valid non-serious case received from a physician. This case involves a 58 days old female patient who is almost 2 months old, and was inadvertently administered a 0.5 ml dose of fluzone quadrivalent from the 5ml multi-dose vial today (14 jan 2022). while receiving vaccine INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED [FLUZONE QUADRIVALENT MULTIDOSE]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED lot UJ695AA via unknown route in unknown administration site. On 14-JAN-2022 the patient developed a non-serious patient is almost 2 months old, and was inadvertently administered a 0.5 ml dose of fluzone quadrivalent from the 5ml multi-dose vial today (14 jan 2022). (product administered to patient of inappropriate age) (unknown latency) following the administration of INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED. Action taken was not applicable. It was not reported if the patient received a corrective treatment for the event (Patient is almost 2 months old, and was inadvertently administered a 0.5 mL dose of Fluzone Quadrivalent from the 5mL multi-dose vial today (14 Jan 2022).). At time of reporting, the outcome was Unknown for the event patient is almost 2 months old, and was inadvertently administered a 0.5 ml dose of fluzone quadrivalent from the 5ml multi-dose vial today (14 jan 2022).. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.